BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related ...
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...
HENDERSON, NV, Aug 10, 2022 – BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company ...
HENDERSON, Nev., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. (“BioLife” or the “Company”) (OTC: BLFE) announced today that it will be expanding the scope of its orthomolecular medicine and ...
BOTHELL, Wash., Jan. 22, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene ...
An acquisition spree has produced a host of problems, costs, write-offs, a collapse in gross margins and profits, cash bleed, and significant dilution. While only the evo and Sexton acquisitions have ...
Henderson, Nevada, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire-- BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has finalized a definitive agreement (the “Agreement”) with Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results